Showing 1971-1980 of 4063 results for "".
- Novaliq Announces More Than Half of Patients Enrolled in CyclASol Phase 3 Dry Eye Disease Trial ESSENCE-2https://modernod.com/news/novaliq-announces-more-than-half-of-patients-enrolled-in-cyclasol-phase-3-dry-eye-disease-trial-essence-2/2479125/Novaliq announced today that the second Phase 3 clinical trial evaluating CyclASol to treat the signs and symptoms of dry eye disease (DED) has randomized more than 50% out of 834 targeted patients, with top-line results expected in the second half of 2021. The Phase 3 program for CyclASol
- The Allergan Foundation Donates $2 Million to Community Organizations on Front Line of COVID-19 Responsehttps://modernod.com/news/the-allergan-foundation-donates-2-million-to-community-organizations-on-front-line-of-covid-19-response/2477485/Allergan announced that The Allergan Foundation has awarded approximately $13 million in charitable grants in 2020. The 2020 donations support programs dedicated to the COVID-19 pandemic response, as well as initiatives supporting mental health, eye care, and breast
- Expanding Product Needs, Surgery Growth Will Drive Retinal Surgical Device Market to Nearly $2 Billion by 2025https://modernod.com/news/expanding-product-needs-surgery-growth-will-drive-retinal-surgical-device-market-to-nearly-2-billion-by-2025/2477308/Ophthalmologists use more specialized products in retinal surgeries than other subspecialties, producing more revenue per procedure than segments with higher surgical volume. As a result, the retinal surgical device market is expected to total more than $1.57 billion in 2020, with revenue rising
- Ocuphire Pharma Announces Results from Two Phase 2 Clinical Studies of Nyxol Eye Dropshttps://modernod.com/news/ocuphire-pharma-announces-results-from-two-phase-2-clinical-studies-of-nyxol-eye-drops/2477075/Ocuphire Pharma announced statistically significant and clinically meaningful results from its recently completed two phase 2b studies of its lead drug candidate, Nyxol Eye Drops. Topline results of the primary and secondary endpoints of the MIRA-1 and ORION-1 studies provided confirmatory
- Oyster Point Announces Positive Results from Phase 2 Clinical Trial of Investigational Treatment for Dry Eye Diseasehttps://modernod.com/news/oyster-point-pharma-announces-positive-results-from-phase-2-clinical-trial-of-investigational-treatment-for-dry-eye-disease/2480029/Oyster Point Pharma announced results from the PEARL study, a phase 2b clinical trial evaluating the company’s novel therapy for the treatment of dry eye disease (DED). The study met both sign and symptom primary endpoints by showing a statistically significant improvement in each compared to a v
- US Plans to Ship First Coronavirus Vaccines Within 24 Hours of FDA Approvalhttps://modernod.com/news/us-plans-to-ship-first-coronavirus-vaccines-within-24-hours-of-fda-approval/2478291/US officials on Wednesday indicated that a COVID-19 vaccine will start to be distributed within about 24 hours after a license or emergency-use authorization (EUA) is issued. Paul Ostrowski, who is overseeing logistics for the US government’s Operation Warp Speed initiative, said that the o
- CMS Proposes Changes to Docs’ Medicare Payments for 2021, Including Payment Cuts for Some Specialtieshttps://modernod.com/news/cms-proposes-changes-to-docs-medicare-payments-for-2021-including-payment-cuts-for-some-specialties/2478125/Federal health officials released a proposed rule that sets 2021 Medicare payment rates for physicians and includes changes to the Merit-based Incentive Payment System, according to a FierceHealthcare
- Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 ASCRShttps://modernod.com/news/glaukos-technologies-featured-in-numerous-scientific-abstracts-at-the-2022-ascrs/2480788/Glaukos announced that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 22–26, 2022 in Washington, DC. In addition, Glaukos is sponsoring an educational symposium
- Alcon Announces Scientific Program at ASCRS 2022https://modernod.com/news/alcon-announces-scientific-program-at-ascrs-2022/2480782/Alcon will once again have a significant scientific presence at the American Society of Cataract and Refractive Surgery (ASCRS) 2022 annual meeting, taking place April 22-26 in Washington, DC. Approximately 150 abstracts feature Alcon’s leading ophthalmic products and equipment—with m
- Allergan to Present New Data from its Eye Care Portfolio at ASCRS 2022https://modernod.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-ascrs-2022/2480778/Allergan announced that it will present new data from its eye care portfolio at the 2022 ASCRS annual meeting being held April 22–26 in Washington, DC. Presentations will include new data on Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only